Delayed haemolysis after artesunate treatment of severe malaria - Review of the literature and perspective

Travel Medicine and Infectious Disease

Volumn 13, Issue 2, 2015, Pages 143-149

  Rolling, Thierry ^a,b   Agbenyega, Tsiri ^c   Krishna, Sanjeev ^d,e,f   Kremsner, Peter G ^e,f   Cramer, Jakob P ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^c KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^e German Center for Infection Research   (Gabon)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Artemisinins; Artesunate; Delayed haemolysis; Severe malaria

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ DERIVATIVE; ARTESUNATE; HEMOGLOBIN; QUININE; ANTIMALARIAL AGENT;

AGE; AUTOIMMUNITY; COMBINATION CHEMOTHERAPY; COOMBS TEST; DISEASE SEVERITY; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; HEMOLYSIS; HUMAN; MALARIA; PARASITEMIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TRAVEL;

ANTIMALARIALS; ARTEMISININS; HEMOLYSIS; HUMANS; MALARIA;

EID: 84926421824     PISSN: 14778939     EISSN: 18730442     Source Type: Journal    
DOI: 10.1016/j.tmaid.2015.03.003     Document Type: Review

References (34)

1. A. Dondorp, F. Nosten, K. Stepniewska, N. Day, and N. White Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial Lancet 366 9487 2005 717 725
2. A.M. Dondorp, C.I. Fanello, I.C. Hendriksen, E. Gomes, A. Seni, and K.D. Chhaganlal Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial Lancet 376 9753 2010 1647 1657
3. D. Sinclair, S. Donegan, R. Isba, and D.G. Lalloo Artesunate versus quinine for treating severe malaria Cochrane Database Syst Rev 6 2012 CD005967
4. T. Rolling, D. Wichmann, S. Schmiedel, G.D. Burchard, S. Kluge, and J.P. Cramer Artesunate versus quinine in the treatment of severe imported malaria: comparative analysis of adverse events focussing on delayed haemolysis Malar J 12 2013 241
5. H.O. AlKadi Antimalarial drug toxicity: a review Chemotherapy 53 6 2007 385 391
6. J.P. Cramer, R. Lopez-Velez, G.D. Burchard, M.P. Grobusch, and P.J. de Vries Treatment of imported severe malaria with artesunate instead of quinine-more evidence needed? Malar J 10 2011 256
7. World Health Organization (WHO) Guidelines for the treatment of malaria, second edition 2010 [Geneva, Switzerland]
8. K. Morch, O. Strand, O. Dunlop, A. Berg, N. Langeland, and R.A. Leiva Severe malaria and artesunate treatment, Norway Emerg Infect Dis 14 11 2008 1816 1818
9. M.M. Paczkowski, K.L. Landman, and P.M. Arguin Update on cases of delayed hemolysis after parenteral artesunate therapy for malaria - United States, 2008 and 2013 MMWR Morb Mortal Wkly Rep 63 34 2014 753 755
10. T. Zoller, T. Junghanss, A. Kapaun, I. Gjorup, J. Richter, and M. Hugo-Persson Intravenous artesunate for severe malaria in travelers, Europe Emerg Infect Dis 17 5 2011 771 777
11. P.M. Arguin Case definition: postartemisinin delayed hemolysis Blood 124 2 2014 157 158
12. J. Van den Ende, G. Coppens, T. Verstraeten, T. Van Haegenborgh, K. Depraetere, and A. Van Gompel Recurrence of blackwater fever: triggering of relapses by different antimalarials Trop Med Int Health 3 8 1998 632 639
13. T.T.H. Chau, N.P.J. Day, L. Van Chuong, N.T.H. Mai, P.P. Loc, and N.H. Phu Blackwater fever in southern Vietnam: a prospective descriptive study of 50 cases Clin Infect Dis 23 6 1996 1274 1281
14. K. Ritter, A. Kuhlencord, R. Thomssen, and W. Bommer Prolonged haemolytic anaemia in malaria and autoantibodies against triosephosphate isomerase Lancet 342 8883 1993 1333 1334
15. T. Rolling, T. Agbenyega, S. Issifou, A.A. Adegnika, J. Sylverken, and D. Spahlinger Delayed hemolysis after treatment with parenteral artesunate in African children with severe malaria-a double-center prospective study J Infect Dis 209 12 2014 1921 1928
16. S. Jaureguiberry, P.A. Ndour, C. Roussel, F. Ader, I. Safeukui, and M. Nguyen Postartesunate delayed hemolysis is a predictable event related to the lifesaving effect of artemisinins Blood 124 2 2014 167 175
17. A.R. Kreeftmeijer-Vegter, P.J. van Genderen, L.G. Visser, W.F. Bierman, J. Clerinx, and C.K. van Veldhuizen Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium Malar J 11 2012 102
18. P. Caramello, R. Balbiano, T. De Blasi, M. Chiriotto, M. Deagostini, and G. Calleri Severe malaria, artesunate and haemolysis J Antimicrob Chemother 67 8 2012 2053 2054
19. L. Raffray, M.C. Receveur, M. Beguet, P. Lauroua, T. Pistone, and D. Malvy Severe delayed autoimmune haemolytic anaemia following artesunate administration in severe malaria: a case report Malar J 13 1 2014 398
20. M. Eder, H. Farne, T. Cargill, A. Abbara, and R.N. Davidson Intravenous artesunate versus intravenous quinine in the treatment of severe falciparum malaria: a retrospective evaluation from a UK centre Pathogens Glob Health 106 3 2012 181 187
21. Centers for Disease Control and Prevention Published reports of delayed hemolytic anemia after treatment with artesunate for severe malaria - worldwide, 2010-2012 MMWR Morb Mortal Wkly Rep 62 2013 5 8
22. Deutsche Gesellschaft für Tropenmedizin und Internationale Gesundheit (DTG) Leitlinie: Diagnostik und Therapie der Malaria 2011 cited 2012; Available from: http://www.awmf.org/uploads/tx-szleitlinien/042-001l-S1-Malaria-2011-08-01.pdf
23. C. Burri, G. Ferrari, H.M. Ntuku, A.T. Kitoto, S. Duparc, and P. Hugo Delayed anemia after treatment with injectable artesunate in the democratic Republic of the Congo: a manageable issue Am J Trop Med Hyg 91 4 2014 821 823
24. Agence nationale de sécurité du médicament et des produits de santé (ansm) ATU nominative, protocole d'utilisation thérapeutique et de recueil d'informations, Malacef® (artésunate) 60mg, poudre et solvant pour solution injectable 2013 [cited 2014 30/09/2014]; Available from: http://ansm.sante.fr/var/ansm-site/storage/original/application/01d138a64031bcf9f37fa2737308caa5.pdf
25. A. Corpolongo, P. De Nardo, P. Ghirga, E. Gentilotti, R. Bellagamba, and C. Tommasi Haemolytic anaemia in an HIV-infected patient with severe falciparum malaria after treatment with oral artemether-lumefantrine Malar J 11 2012 91
26. I. Sagara, R. Piarroux, A. Djimde, R. Giorgi, K. Kayentao, and O.K. Doumbo Delayed anemia assessment in patients treated with oral artemisinin derivatives for uncomplicated malaria: a pooled analysis of clinical trials data from Mali Malar J 13 1 2014 358
27. K. Rehman, F. Lotsch, P.G. Kremsner, and M. Ramharter Haemolysis associated with the treatment of malaria with artemisinin derivatives: a systematic review of current evidence Int J Infect Dis 29 2014 268 273
28. P.A. Buffet, I. Safeukui, G. Deplaine, V. Brousse, V. Prendki, and M. Thellier The pathogenesis of Plasmodium falciparum malaria in humans: insights from splenic physiology Blood 117 2 2011 381 392
29. P. Newton, K. Chotivanich, W. Chierakul, R. Ruangveerayuth, P. Teerapong, and K. Silamut A comparison of the in vivo kinetics of Plasmodium falciparum ring-infected erythrocyte surface antigen-positive and -negative erythrocytes Blood 98 2001 450 457
30. T. Rolling, S. Schmiedel, D. Wichmann, D. Wittkopf, G.D. Burchard, and J.P. Cramer Post-treatment haemolysis in severe imported malaria after intravenous artesunate: case report of three patients with hyperparasitaemia Malar J 11 1 2012 169
31. G. Garratty Immune hemolytic anemia associated with drug therapy Blood Rev 24 4-5 2010 143 150
32. T.T. Hien, and N.J. White Qinghaosu Lancet 341 8845 1993 603 608
33. S. Finaurini, N. Basilico, Y. Corbett, S. D'Alessandro, S. Parapini, and P. Olliaro Dihydroartemisinin inhibits the human erythroid cell differentiation by altering the cell cycle Toxicology 300 1-2 2012 57 66
34. J.B. Tapko, B. Toure, and L.G. Sambo Status of blood safety in the WHO African region: report of the 2010 survey 2014 WHO Regional Office for Africa Brazzaville, Republic of Congo